RNA, U2 small nuclear 18, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-18P profile across patient tissues and cancer cell-line models. RNU2-18P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNU2-18P is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RNU2-18P RNA expression shows 6,380 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KIRC, and STAD as cancer lineages where RNU2-18P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-18P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-18P survival associations across molecular data types. RNU2-18P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-18P RNA expression–survival associations across cancer types. High RNU2-18P expression shows unfavorable associations in ACC, BLCA, UVM, HNSC, LIHC and PCPG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNU2-18P RNA expression.
This table summarizes RNU2-18P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-18P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-18P shows lower tumor expression in PAAD and ESCA and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher RNU2-18P RNA expression in tumor versus normal tissue (log2 FC = +0.121, t-test p = .007).
This table shows molecular features associated with RNU2-18P in patient tissues and cancer cell lines. In patient samples, RNU2-18P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
